Magnifying Human Potential: AbCellera is Breaking Barriers to Transform Healthcare with Revolutionary Antibody Therapies

AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners.

Driving Innovation in Medicine

Delivering impactful treatments for patients worldwide is at the core of AbCellera's mission. Their revolutionary work focuses on creating breakthrough antibody medicines that have the potential to revolutionize healthcare.

AbCellera’s Cutting-Edge Platforms

AbCellera's groundbreaking technology platforms serve as the foundation for their groundbreaking discoveries. These platforms enable the exploration of high-value drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs.

Unlocking GPCRs & Ion Channels: By leveraging their platform, AbCellera is at the forefront of developing first-in-class antibody medicines targeting complex transmembrane protein targets previously deemed intractable.

Groundbreaking T-Cell Engagers: AbCellera's T-cell engager platform harnesses a vast array of CD3-binding antibodies to craft bispecific antibodies capable of potent tumor-cell killing while minimizing cytokine release, addressing potential dose-limiting toxicities.

Expanding Target Space with Peptide-MHCs: Their advanced technology enables the discovery of antibodies highly specific to MHC-peptide complexes, broadening the target scope for T-cell engagers, particularly in solid tumors.

Powering Progress

AbCellera's engine represents a sophisticated infrastructure designed to streamline the intricate path from identifying therapeutic targets to delivering treatments to patients. By seamlessly integrating expert teams, high-tech technology, and modern facilities with data science and automation, AbCellera facilitates optimized workflows crucial for advancing therapeutic programs from conception to clinical fruition.

Empowering Drug Development

The AbCellera engine empowers the progression of drug programs through to the development of development candidates primed for IND-enabling studies. Currently, the company is in the process of integrating key elements such as process development, manufacturing, and regulatory capabilities. Once this integration is complete, AbCellera will possess the capability to shepherd programs from target identification to early clinical development stages.

Discovering Therapeutic Gems

Under the discovery phase, AbCellera employs a multi-faceted approach to identify antibodies derived from natural immune responses. This includes techniques such as immunization across various species, including rats, wild-type and humanized mouse platforms, camelids, and more. Screening and sequencing are then conducted using high-throughput single-cell screening powered by advanced machine vision and sequencing technologies. The process culminates in the identification of lead panels through high-throughput functional and biophysical characterization.

Developing Optimal Clinical Candidates

In the development phase, AbCellera focuses on selecting the most promising clinical candidates. This involves a rigorous selection process supported by mid-scale expression and detailed characterization to identify development candidates. Subsequently, clinical candidates are chosen through large-scale expression, IND-enabling studies, and CMC (Chemistry, Manufacturing, and Controls) development, ensuring optimal readiness for clinical trials.

Advancing Medical Solutions

AbCellera's firm commitment to innovation and progress is epitomized by its robust internal pipeline. The pipeline showcases a diverse array of promising programs aimed at addressing unmet medical needs across various therapeutic areas. Among these, ABCL575 and ABCL635 stand out as two preclinical programs currently undergoing critical IND-enabling studies. These studies mark a pivotal step toward advancing these programs toward clinical trials, with submissions for IND anticipated in 2025.

Moreover, AbCellera is poised for further expansion and diversification of its pipeline, with plans to introduce additional development candidates into similar IND-enabling studies in 2024 and 2025. This strategic move underscores the company's proactive approach to continuously augmenting its portfolio of potential therapies, ensuring a steady stream of inventive solutions for patients in need.

The Path Ahead

In anticipation of future growth and to support the advancement of its pipeline programs, AbCellera is embarking on a significant expansion initiative. Central to this endeavor is the establishment of a trailblazing clinical manufacturing facility, slated for completion in 2025. Strategically located near the company's headquarters, this state-of-the-art facility will play a pivotal role in bolstering AbCellera's capabilities in producing GMP (Good Manufacturing Practice) drug substances.

Equipped with bioreactors boasting capacities of up to 2,000 liters, the manufacturing facility will enable AbCellera to scale up production efficiently and effectively. Additionally, the facility will accommodate drug product manufacturing, further enhancing the company's end-to-end capabilities in delivering high-quality therapeutic solutions.

Through these strategic initiatives, AbCellera reaffirms its commitment to advancing innovative therapies and improving patient outcomes. By expanding its pipeline and enhancing manufacturing capabilities, AbCellera is poised to shape the future of biopharmaceutical development and make a meaningful impact in the healthcare landscape.

Carl Hansen, Chairman, CEO, & President, AbCellera

Carl Hansen, with a multidisciplinary approach at the intersection of engineering, biology, and computation, has made significant contributions evident in over 90 peer-reviewed manuscripts and abstracts, as well as more than 75 patent applications and the successful launch of nine commercial products. Notably recognized as EY Canada’s Entrepreneur of the Year, Carl's entrepreneurial journey began with the co-founding of Precision Nanosystems, a prominent player in technologies for non-viral delivery of genomic medicines, including mRNA vaccines and therapeutics. Holding the position of adjunct professor at the University of British Columbia and having served on the Scientific Advisory Board of Fluidigm Corp, Carl obtained his Ph.D. in Applied Physics/Biotechnology from Caltech, complemented by a BASc in Engineering Physics and Honors Mathematics from the University of British Columbia.

Pushing the boundaries of antibody discovery, AbCellera collaborates with partners to tackle the world’s most pressing medical challenges.